drugset
drugset / Trial / NCT05749302

Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins

NCT05749302 ↗

Phase 2/3 Unknown 500 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelDiagnostic

Summary

This is an open-label whole-body PET/CT study for investigating the value of Al18F-NOTA-FAPI PET/CT in patients with malignant tumors expressing fibroblast-activated proteins

Timeline

Start
2023-01-08
Primary completion
2025-03-08
Completion
2026-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FAPI Diagnostic / imaging agent — —

Indications

cancer